RiverPark Advisors LLC Purchases New Shares in HealthEquity, Inc. (NASDAQ:HQY)

RiverPark Advisors LLC acquired a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,814 shares of the company’s stock, valued at approximately $230,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HQY. Janney Montgomery Scott LLC grew its position in shares of HealthEquity by 27.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,970 shares of the company’s stock worth $324,000 after buying an additional 855 shares during the period. US Bancorp DE grew its position in shares of HealthEquity by 4.8% during the 1st quarter. US Bancorp DE now owns 11,489 shares of the company’s stock worth $938,000 after buying an additional 521 shares during the period. ProShare Advisors LLC grew its position in shares of HealthEquity by 5.7% during the 1st quarter. ProShare Advisors LLC now owns 19,477 shares of the company’s stock worth $1,590,000 after buying an additional 1,053 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of HealthEquity by 11.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 26,663 shares of the company’s stock worth $2,177,000 after buying an additional 2,660 shares during the period. Finally, Nicolet Advisory Services LLC acquired a new position in shares of HealthEquity during the 1st quarter worth about $268,000. 99.55% of the stock is owned by institutional investors.

Insider Transactions at HealthEquity

In related news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the sale, the director now owns 54,719 shares in the company, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Frank Corvino sold 1,039 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the completion of the sale, the director now owns 3,784 shares in the company, valued at approximately $363,642.40. This trade represents a 21.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,536 shares of company stock worth $884,517 in the last 90 days. Corporate insiders own 2.20% of the company’s stock.

HealthEquity Trading Up 3.4 %

NASDAQ HQY opened at $98.98 on Friday. HealthEquity, Inc. has a 52 week low of $62.10 and a 52 week high of $101.17. The stock has a market capitalization of $8.64 billion, a price-to-earnings ratio of 82.48, a PEG ratio of 1.55 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. The stock’s 50 day moving average price is $85.02 and its two-hundred day moving average price is $81.08.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The company had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. As a group, analysts anticipate that HealthEquity, Inc. will post 2.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

HQY has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft boosted their target price on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Bank of America boosted their price objective on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday. BTIG Research boosted their price objective on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday. The Goldman Sachs Group began coverage on HealthEquity in a research report on Friday. They issued a “neutral” rating and a $108.00 price objective for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $92.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, HealthEquity presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.23.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.